Board Of Directors
SGC Board of Directors (Phase III)
Prof. Markus Grütter (Chair)
University Professor, Biochemistry
Vice Dean of Research and Planning, Medical FacultyUniversity of Zurich, Switzerland
Role on Board: Chair
Nominating organisation: Independent
Dr. Tim Willson
Director of Chemical Biology, GSK
Role on Board: Director
Nominating organisation: GSK
Dr. Hans Widmer
Executive Director, Academic Liaison and Knowledge Management, Novartis Institutes for BioMedical Research
Role on Board: Director
Nominating organisation: Novartis
Dr. Mark Bunnage
Vice President, Head of Chemistry and Biotherapeutics Research, Pfizer
Role on Board: Director
Nominating organisation: Pfizer
Dr. Cindy Bell
Executive Vice President, Corporate Development, Genome Canada
Role on Board: Director
Nominating organisation: Genome Canada
Dr. Stephen Burley
Senior Vice President Research, Eli Lilly
Role on Board: Director
Nominating organisation: Eli Lilly
Dr. Michael Dunn
Head of Molecular and Physiological Sciences, Wellcome Trust
Role on Board: Director
Nominating organisation: Wellcome Trust
Dr. Paul Lasko
Scientific Director, CIHR-Institute of Genetics IRSC-Institut de génétique
Role on Board: Director
Nominating organisation: CIHR
Ms Alison Barr or Mr Craig Fowler or Ms Jane Kirkwood
Director - Research Branch, Ontario Ministry of Research and Innovation
Role on Board: Observer
Nominating organisation: OMRI
Dr. Kirk Clark
Executive Director, Protein Structure Group, Novartis Institutes for Biomedical Research
Role on Board: Non-directorial member (
Nominating organisation: Novartis
Prof. Aled Edwards
CEO, SGC
Role on Board: Management Team
Nominating organisation: SGC
Dr. Chas Bountra
CSO (Oxford), SGC
Role on Board: Management Team
Nominating organisation: SGC Oxford
Dr. Cheryl Arrowsmith
CSO (Toronto), SGC
Role on Board: Management Team
Nominating organisation: SGC Toronto
Dr. Meher Antia
Science Portfolio Adviser, Wellcome Trust
Role on Board: Secretary
Nominating organisation: Independent
